Press Release
Printer-Friendly
News |
SAS® powers small, midsize biotech and pharmaceutical companiesLife Science companies invest more in analytics for new drug developmentCARY, NC (Mar. 18, 2009) – Despite the recession, pharmaceutical and biotech companies continue to invest in discovery and development of advanced, life-saving therapies. Small and midsize life science firms leading the quest to deliver innovative products use SAS analytics to speed drug development and facilitate regulatory compliance. “Drug discovery and clinical trials entail years of work and millions of start-up dollars,” said Jason Burke, Worldwide Director of Health and Life Sciences at SAS. “For small and midsize firms with limited capital and staffing, ease of regulatory compliance, analysis and insight is paramount. And new drugs from these startup firms are driving growth at many top 10 pharmaceutical companies today.” Companies that have recently acquired SAS Analytics include Acadia Pharmaceuticals Inc., Agreliant Genetics, Aids Vaccine Initiative Inc., Alba Therapeutics Corp., Alita Pharmaceuticals Inc.,Arca Biopharma, Avalere Health LLC., Cenomed Biosciences LLC., Cougar Biotechnology Inc., Cypress Biosciences Inc., Cytokinetics Inc., Durect Corp., Endocyte, Int’l Limerick Neurosciences Inc., Keryz Biopharmaceuticals Inc., Lux Biosciences Inc., Map Pharmaceuticals Inc., Medicinova Inc., Medtrial Inc., Molecular Insight Pharmaceuticals Inc., Nastech Pharmaceutical Co Inc., Pharmatech Inc., Procyon Pharmaceuticals Inc., Quark Pharmaceuticals Inc., QuatRx Pharmaceuticals Co., Sapphire Pervasis Therapeutics Inc., Soal Pharmtech Solutions LLC., Sucampo Pharmaceuticals Inc., Therapeutics Inc., and Xenoport Inc. “SAS is the de facto industry standard analysis tool for clinical information,” said Ron Ellis, CEO of Endocyte. “We chose SAS because it makes no sense to invest millions of dollars in clinical studies and not use the best tool available, SAS, to analyze that data.” SAS continues to expand its focus on the small-medium business (SMB) market. Its channel partner program and targeted SMB pricing bundles enable SAS resellers to deliver powerful SAS software to any industry, including life sciences. Part of SAS’ overall channel efforts, The SAS reseller program also includes service providers and OEMs, to increase SAS awareness to SMBs while generating new sales for SAS. “Many SAS channel partners focus on this industry, including Alpha Professional Services, d-Wise Technologies, MAJARO InfoSystems, Inc. and PluralSoft. These resellers are combining life sciences expertise and SAS knowledge so smaller businesses can leverage the same powerful SAS business analytics as larger corporations,” added Burke. An integrated suite of solutions for life sciencesSAS solutions for life sciences address each stage of bringing a drug to market. SAS’ portfolio of integrated solutions drives efficiencies and deeper insights throughout a drug's lifecycle: from discovery through development, commercialization and beyond. Globally recognized as the industry leader in analytics, SAS is the de facto standard for clinical data analysis and the choice of every FORTUNE 500® life sciences company. SAS is synonymous with accurate, comprehensive, and reliable analysis of pharmaceutical research and business data.
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions delivered within an integrated framework, SAS helps customers at more than 45,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world
The Power to Know®
.
|
Editorial Contacts:
Visit the SAS Press Center for more information. |